Company Filing History:
4 out of 263 
4 out of 987 
2 out of 167 Years Active: 2018-2023
Title: Sebastian Kroll: Innovator in CDK Inhibition
Introduction
Sebastian Kroll is a notable inventor based in London, GB. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit cyclin-dependent kinases (CDKs). With a total of 4 patents to his name, Kroll's work has the potential to impact various therapeutic areas.
Latest Patents
Kroll's latest patents focus on pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that serve as CDK inhibitors. These compounds target multiple CDKs, including CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, and CDK13. The patents disclose pharmaceutical compositions that utilize these compounds to treat disorders associated with CDK activity, such as cancer, viral infections, neurodegenerative disorders, ischaemia, renal diseases, and cardiovascular disorders. The treatment may also involve simultaneous or sequential administration of additional active agents, enhancing the therapeutic efficacy.
Career Highlights
Throughout his career, Kroll has worked with esteemed organizations, including Cancer Research Technology Limited and Emory University. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Kroll has collaborated with notable colleagues, including Alexander Bondke and Anthony Barrett. These partnerships have further enriched his research and development efforts in the pharmaceutical domain.
Conclusion
Sebastian Kroll's innovative work in CDK inhibition showcases his commitment to advancing medical science. His contributions have the potential to lead to significant improvements in the treatment of various diseases.